Table 1

Demographic and clinical variables for patients with SLE and control subjects

Demographic variablesSLE(n = 94)Controls(n = 11)
Age
    Range (years)18–7925–58
    Mean (SD), (median)39.7 (14.8), (39.1)39.8 (11.6), (39.0)
Gender, n (%) female83 (88.0)10 (91.0)
Ethnicity, n (%)
    Caucasian41 (43.6)4 (36.4)
    African-Canadian21 (22.3)2 (18.2)
    Asian21 (22.3)4 (36.4)
    Other11 (11.7)1 (9.1)
Clinical features*, n (%)
    Rash19 (20.2)NA
    Mucocutaneous10 (10.6)NA
    Alopecia14 (14.9)NA
    Arthritis12 (12.8)NA
    Serositis2 (2.1)NA
    Nephritis (⩾1 SLEDAI-2K criteria)36 (38.3)NA
    Vasculitis7 (7.4)NA
    Cerebritis1 (1.1)NA
Medications*
    Prednisone†, mean (SD), (median), mg/day12.5 (15), (7.5)NA
    Antimalarials, n (%)64 (68.0)NA
    Azathioprine, n (%)20 (21.3)NA
    Mycophenolate mofetil, n (%)10 (10.6)NA
    Methotrexate, n (%)5 (5.3)NA
    Cyclosporine, n (%)2 (2.1)NA
  • *Clinical variables and treatment recorded at first clinical assessment.

  • †No patients received pulse steroids over the course of the study.

  • n, number of patients; NA, not applicable; SD, standard deviation; SLE, systemic lupus erythematosus; SLEDAI, SLE disease activity index.